Serum antibody levels to SARS-CoV-2 receptor-binding domain

• Published in: PloS one 2023-11, Vol.18 (11), p.e0288713
• Main Authors: Hau, Derrick, Pflughoeft, Kathryn J, Gates-Hollingsworth, Marcellene A, Kaur, Simranjit, Hill, Haydon J, Arias-Umana, Jose, Chung, Chelsea C, Smith, Valerie L, Riddle, Mark S, Healy, Sara A, AuCoin, David P
• Format: Article
• Language: English
• Subjects: Antibodies; Biological products; Enzyme-linked immunosorbent assay; Enzymes; Evaluation; Health aspects; Immunoassay; Infection; Medical colleges; Medical research; Medicine, Experimental; Vaccination; Viral antibodies
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0288713

Antibodies reactive with the SARS-CoV-2 receptor-binding domain (RBD) of the spike protein are associated with viral neutralization, however low antibody titers, specifically against SARS-CoV-2 variants, may result in reduced viral immunity post naturally acquired infection. A cohort study comprised of 121 convalescent individuals from northern Nevada was conducted looking at anti-RBD antibody levels by enzyme-linked immunosorbent assay. Serum was collected from volunteers by staff at the University of Nevada, Reno School of Medicine Clinical Research Center and assessed for antibodies reactive to various SARS-CoV-2 RBD domains relevant to the time of the study (2020-2021). A nonpaired group of vaccinated individuals were assessed in parallel. The goal of the study was to identify antibody levels against the RBD subunit in convalescent and vaccinated individuals from northern Nevada.